Authors: Renee Botello, MSc, Treatment and Trial Navigator; Daniel A. Saez, MSc, Manager of LungMATCH Navigation Program In 2022, the treatment landscape for lung cancer continued to evolve to provide breakthrough treatment options for people living with lung cancer. This [...]
Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program For many years, the treatment options given to patients diagnosed with early stage non-small cell lung cancer (NSCLC) was limited to surgery with or without chemotherapy to improve outcomes. However, [...]
What happens when your cancer becomes resistant to your course of treatment and progresses? That’s the question we explored in the September episode of our Lung Cancer Living Room series. Dr. David Gandara, professor emeritus and co-director of UC [...]
Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program Many patients with non-small cell lung cancer (NSCLC) rely on a class of treatments called immunotherapy to battle their cancer. The significant difference between immunotherapy and targeted therapy (the other [...]
Authors: Andrew Ciupek, PhD, Associate Director, Clinical Research and Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program People who are diagnosed with early stage (stage 1-2) non-small cell lung cancer (NSCLC) are generally broken down into two groups: those [...]
GO2 for Lung Cancer team pictured: Joelle Fathi, DNP, RN, ARNP, FAAN; Daniel Saez, MSc; Jennifer C. King, PhD By Jennifer C. King, PhD, Chief Scientific Officer and Daniel Saez, MSc, Manager, LungMATCH Navigation Program The [...]
Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program, GO2 for Lung Cancer Immunotherapy, a type of treatment that helps the body’s own immune system fight cancer, is often discussed as a first line of treatment for people with [...]
Despite 2021 being another challenging year, we saw treatment options for lung cancer increase by leaps and bounds. In 2021 the treatment landscape for lung cancer evolved to provide breakthrough treatment options targeting mutations that were previously unavailable for [...]
Author: Andrew Ciupek, PhD, Senior Manager of Clinical Research, GO2 for Lung Cancer The 2021 World Conference on Lung Cancer (WCLC) saw several research presentations that helped increase our understanding of immunotherapy as a treatment for people with lung [...]
On October 15th, 2021, the Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) for treatment following surgery and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression ≥ 1% as determined by a FDA-approved test. The [...]